Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial...
NEWTON, Mass., Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among […]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price […]
Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification